Catalyst Event

Amgen Inc (AMGN) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/7/2026, 12:00:00 AM

OtherSentiment: Positive

Amgen presented new Phase 3 subgroup data for Repatha at the American Diabetes Association (ADA) conference, showing it reduced the risk of first major cardiovascular events by 29% in high-risk diabetic patients without a prior heart attack or stroke.

Korean Translation

암젠, 미국 당뇨병 학회(ADA)에서 레파타(Repatha)에 대한 새로운 3상 하위 그룹 데이터를 발표함. 데이터에 따르면, 심장마비나 뇌졸중 병력이 없는 고위험 당뇨병 환자에서 첫 주요 심혈관 사건 발생 위험을 29% 감소시킴.

Related Recent Events

View Full Timeline